(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical ...

回归本次交易的本质，和铂医药与Windward Bio完成的NewCo交易颇具里程碑意义。自此之后，和铂医药的盈利模式除了传统的两种外，又多了一项潜在的股权退出收益，这也意味着和铂医药的盈利能力在NewCo交易的推动下拥有了更高的增长潜力。

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Investing.com -- GSK Plc的首席执行官Emma ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Investing.com -- 英国制药公司GSK周一宣布，计划以高达11.5亿美元收购总部位于波士顿的生物制药公司IDRx。此举是GSK持续加强其在胃肠道癌症领域产品组合的一部分。 错过一次，就可能与财富翻倍的机会擦肩而过！用ProPicks，提前布局，6种AI选股模型助你今年的投资大放异彩！

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.